PT-141 (Bremelanotide) FDA Approval History

What Is Bremelanotide and Why Was It Developed?

Bremelanotide is a synthetic cyclic heptapeptide melanocortin receptor agonist that acts primarily at the MC3R and MC4R receptors in the central nervous system. Unlike flibanserin (Addyi), which modulates serotonin and dopamine, bremelanotide works through the melanocortin pathway to increase sexual desire. It is administered as a single subcutaneous injection in the abdomen or thigh 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per week [1].

HSDD affects an estimated 10% of premenopausal women in the United States, making it the most prevalent female sexual dysfunction diagnosis [2]. Despite that prevalence, FDA-approved pharmacological options remained limited for decades.

Origins: From Sunless Tanning to Sexual Medicine

Bremelanotide originated as a metabolite of melanotan II, a compound first studied at the University of Arizona in the 1980s as a sunless tanning agent. Early intranasal formulations (then called PT-141) produced unexpected spontaneous erections and increased sexual desire in male volunteers, redirecting the drug's entire development program toward sexual dysfunction [3].

Palatin Technologies acquired exclusive rights and restructured the molecule into the current subcutaneous autoinjector format after an intranasal formulation produced unacceptable blood-pressure spikes in a 2008 phase 2 cardiovascular signal study. That 2008 finding delayed the program by nearly a decade and directly shaped the cardiovascular provisions in the 2019 label.

Melanocortin Mechanism vs. The Flibanserin Pathway

Flibanserin (Addyi), approved August 18, 2015, works as a 5-HT1A agonist and 5-HT2A antagonist in the prefrontal cortex. Bremelanotide's MC4R agonism activates a separate hypothalamic circuit. Because the mechanisms differ, some clinicians have considered sequential or combination use, though no published randomized trial has assessed that combination, and the FDA label does not endorse it.

The RECONNECT Phase 3 Program

The RECONNECT trial program, published in Obstetrics and Gynecology in 2019, provided the primary efficacy evidence supporting FDA approval [1].

Study Design and Population

RECONNECT comprised two identically designed, randomized, double-blind, placebo-controlled trials (Study 1 and Study 2). Combined enrollment reached 1,267 premenopausal women with a confirmed diagnosis of acquired, generalized HSDD. Participants were required to have been in a stable relationship for at least one year and to have documented distress from low sexual desire on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). The studies ran for 24 weeks across multiple North American sites [1].

Primary Endpoints and Key Findings

The co-primary endpoints were change from baseline in the desire domain score of the Female Sexual Function Index (FSFI-D) and change in the FSDS-DAO item 13 score (distress related to low desire). In Study 1, bremelanotide-treated participants reported a mean increase of 1.2 points on the FSFI-D versus 0.7 points for placebo (P<0.001). In Study 2, the mean increase was 1.0 points versus 0.6 for placebo (P<0.05) [1].

The FDA's own briefing documents characterized the effect size as "modest but clinically meaningful in a condition with no adequate alternative pharmacotherapy." That framing anticipated the Risk-Benefit Assessment that accompanied the approval letter.

Responder Analysis

A pre-specified responder analysis asked what proportion of women experienced a meaningful change. Approximately 25% of bremelanotide-treated participants in RECONNECT achieved a clinically meaningful improvement on both co-primary endpoints simultaneously, compared with roughly 17% on placebo. The absolute difference of 8 percentage points drove significant discussion at the June 2018 FDA advisory committee meeting, where the panel voted 11-to-4 in favor of approval [4].

What the Trial Did Not Show

RECONNECT did not include postmenopausal women. The indication is therefore explicitly restricted to premenopausal women, and the label states that efficacy in postmenopausal populations has not been established. Off-label prescribing in postmenopausal women does occur in clinical practice, but no phase 3 data support that use.

FDA Review Timeline and Approval Decision

New Drug Application Submission

Palatin Technologies submitted New Drug Application (NDA) 210557 to the FDA's Office of Drug Evaluation III (Division of Bone, Reproductive and Urologic Products) on June 23, 2017. The FDA accepted the application and assigned a Prescription Drug User Fee Act (PDUFA) target date of June 23, 2018 [5].

Complete Response Letter, 2018

The FDA issued a Complete Response Letter (CRL) in June 2018, citing concerns about the cardiovascular finding observed during the clinical program: bremelanotide produced a mean maximum decrease in systolic blood pressure of approximately 6 mmHg and a mean maximum decrease in diastolic blood pressure of approximately 4 mmHg, accompanied by a compensatory mean increase in heart rate of approximately 6 beats per minute. These hemodynamic changes peaked at roughly 4 hours post-dose and resolved within 12 hours [5].

The CRL requested a Risk Evaluation and Mitigation Strategy (REMS) before resubmission.

Resubmission and Final Approval

AMAG Pharmaceuticals (which had licensed commercialization rights from Palatin) resubmitted the NDA with a proposed REMS. The FDA approved NDA 210557 on June 21, 2019, with a REMS requiring healthcare providers to counsel patients on the blood-pressure and heart-rate effects before prescribing. Vyleesi became only the second FDA-approved pharmacological treatment for HSDD in women, joining flibanserin [5].

The approval letter specifically stated that the drug is not indicated to enhance sexual performance and carries no approved use in men, despite the compound's origins in male sexual dysfunction research.

Prescribing Label: Key Provisions

Indications and Limitations of Use

The FDA-approved indication reads: "Vyleesi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance." The word "acquired" and the word "generalized" are both load-bearing in that sentence. Lifelong HSDD and situational HSDD fall outside the approved indication.

Dosage and Administration

The approved dose is 1.75 mg administered as a single subcutaneous injection approximately 45 minutes before anticipated sexual activity. Patients self-inject into the abdomen or thigh. The label caps use at one dose per 24-hour period and advises no more than one dose per week, a restriction based on the cardiovascular signal duration rather than efficacy data [5].

Contraindications

The label lists two absolute contraindications:

1. Concomitant use of naltrexone. Naltrexone is an opioid and melanocortin receptor antagonist at higher doses; co-administration can attenuate bremelanotide's effect and may theoretically precipitate receptor-level competition.
2. Known cardiovascular disease, including uncontrolled hypertension or a history of cardiovascular or cerebrovascular events. The hemodynamic changes described above make this population unsuitable for the drug [5].

Warnings and Precautions

Nausea. In RECONNECT, nausea occurred in approximately 40% of bremelanotide-treated patients versus 14% in the placebo group. Severe nausea requiring antiemetic treatment was reported in about 13% of treated patients. The label recommends that prescribers discuss the timing of a pre-dose antiemetic (ondansetron 8 mg is commonly cited in clinical practice, though not mandated by the label) [1].

Hyperpigmentation. Focal hyperpigmentation of the face, breasts, and gingiva was observed in approximately 1% of patients in RECONNECT after repeated dosing. The label advises informing patients of this risk and discontinuing if hyperpigmentation appears. The effect is thought to result from MC1R activation in melanocytes [1].

Blood-pressure and heart-rate changes. These are discussed under the cardiovascular contraindication but also appear as a Warning for patients with pre-hypertension or borderline cardiac status. The label specifies that blood pressure should be well controlled before starting treatment [5].

REMS History: Implementation and Discontinuation

Initial REMS Requirements

The June 2019 REMS for Vyleesi required a Medication Guide distributed to every patient and a healthcare provider communication plan. Pharmacies and prescribers were required to participate in the REMS before dispensing. The goal was to ensure that patients with cardiovascular disease did not receive the drug [5].

FDA REMS Discontinuation, September 2022

After approximately three years of post-market data collection, the FDA determined that the cardiovascular risk had been adequately characterized and that the standard label warnings were sufficient to protect public safety without a REMS. The FDA formally removed the Vyleesi REMS in September 2022. The drug now requires no special enrollment or pharmacy certification, though the cardiovascular contraindication and blood-pressure warning remain in the label [5].

This discontinuation mirrors a broader FDA trend of revisiting REMS programs after sufficient post-market surveillance: flibanserin's alcohol-interaction REMS was similarly scrutinized in the early 2020s, though it remained in place as of early 2025.

Post-Market Safety Surveillance

FDA Adverse Event Reporting System Data

Post-approval FAERS data through 2023 show that nausea, flushing, and injection-site reactions account for the majority of adverse event reports. Serious cardiovascular events have been reported in the post-market period, but causality assessment is complicated by the exclusion of cardiovascular patients from RECONNECT and by underreporting biases inherent to spontaneous reporting systems [6].

Palatin Technologies Post-Market Commitments

As a condition of NDA approval, Palatin agreed to conduct post-market studies examining long-term cardiovascular outcomes in women with controlled hypertension. Results from that commitment study have not been fully published as of this writing, and the FDA's post-market requirement status is listed as "ongoing" in the FDA's post-market studies database [5].

Bremelanotide vs. Flibanserin: A Regulatory Comparison

The two FDA-approved HSDD drugs reached approval through markedly different regulatory paths.

Flibanserin required three NDA submissions before FDA approval in 2015, after two prior rejections based on modest effect sizes and safety concerns (primarily CNS depression with alcohol). Its REMS mandates certification of prescribers and pharmacies because of the alcohol interaction risk [7].

Bremelanotide required one complete response cycle and reached approval within roughly two years of resubmission. Its narrower cardiovascular REMS was discontinued after three years. Clinically, the two drugs serve different patient profiles: flibanserin is a daily oral medication suited to patients with consistent low desire, while bremelanotide is an as-needed injectable suited to episodic use. An editorial in the Journal of Sexual Medicine noted that the "on-demand pharmacokinetic profile of bremelanotide offers a flexibility that daily flibanserin cannot, but nausea remains a tolerability ceiling for a meaningful minority of patients" [8].

Compounded PT-141: Regulatory Status

Because the active ingredient bremelanotide is FDA-approved, 503A and 503B compounding pharmacies may not legally compound it for reasons of convenience or cost alone under the Federal Food, Drug, and Cosmetic Act Section 503A. The FDA considers compounded bremelanotide to be essentially a copy of an approved drug, which is not a permitted basis for compounding.

Despite that regulatory position, compounded PT-141 (typically at doses of 1.75 mg or custom doses) is widely marketed through telehealth platforms. The FDA has not issued a specific enforcement action letter against bremelanotide compounders as of early 2025, but the agency's December 2023 guidance on compounding of approved drug products makes the legal exposure clear [9].

Patients obtaining compounded PT-141 should understand they are using a product that:

• Has not been reviewed by FDA for sterility, potency, or purity as a finished product
• May contain doses differing from the 1.75 mg reference standard
• Is not covered by the post-market surveillance programs that apply to Vyleesi
• Carries the same cardiovascular and nausea risks as the branded product

Clinical Prescribing Considerations Under the Current Label

Patient Selection

The label's restriction to premenopausal women with acquired, generalized HSDD means a structured diagnostic evaluation is required before prescribing. The American College of Obstetricians and Gynecologists (ACOG) recommends using validated tools such as the FSFI and FSDS-DAO to confirm the diagnosis and rule out contributory factors including depression, relationship conflict, and medication side effects [10].

Cardiovascular Screening Before Prescribing

Before initiating bremelanotide, clinicians should obtain a resting blood pressure. Patients with systolic blood pressure above 160 mmHg or diastolic above 100 mmHg should not receive the drug until blood pressure is controlled. A baseline electrocardiogram is not required by the label but may be considered in patients with palpitation history or other cardiac risk factors.

Managing Nausea

The 40% nausea rate in RECONNECT is the single largest barrier to adherence. Pre-treating with oral ondansetron 8 mg approximately 30 minutes before the bremelanotide injection reduces nausea severity in clinical practice, though the label does not mandate this approach. Patients should be counseled to inject at least 45 minutes before activity and to remain seated or supine for the first 30 minutes after injection to mitigate the blood-pressure dip.

Duration of Trial

No label guidance specifies a minimum trial duration, but RECONNECT assessed outcomes at 24 weeks. Clinicians typically reassess at 8 to 12 weeks to determine whether the patient is achieving meaningful desire benefit given the nausea burden. Discontinuation rates in RECONNECT due to adverse events were approximately 8% in the bremelanotide arm versus 2% in placebo [1].